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Abstract 
Background: Meta-analyses suggest that schizophrenia patients with a history of cannabis 
use have less impaired cognitive functioning compared to patients without cannabis use.  
 
Aims: To assess the association between recency and frequency of cannabis use and 
cognitive functioning in at-risk mental state for psychosis (ARMS) and First Episode 
Psychosis (FEP) individuals. 
 
Methods: 136 participants completed a cognitive test battery and were assessed for current 
and past cannabis use. Analyses of covariance models where applied to evaluate the main 
effects of cannabis use and patient group (ARMS vs. FEP) as well as their interactions on 
cognitive functioning. 
 
Results: No differences were observed in cognitive performance between current, former 
and never users, and there were no significant interactions between cannabis use and 
patient group. Furthermore, within the group of current cannabis users, frequency of 
cannabis use was not significantly associated with cognitive functioning. 
 
Conclusion: The results of the present study do not support the notion that FEP patients 
and ARMS individuals with a history of cannabis use have less impaired cognitive functioning 
compared to those without cannabis use.  
 
Keywords: First episode psychosis (FEP), at risk mental state (ARMS), cannabis, cognition, 
schizophrenic psychosis. 
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While the cognitively impairing effects of cannabis during acute intoxication have 
been acknowledged for some time, evidence has been accumulating in recent years that 
cannabis may also cause subtle neuropsychological impairments that persist beyond acute 
intoxication (Solowij and Pesa 2010). Recent studies have shown that long-term, heavy 
cannabis use can lead to cognitive deficits in a wide range of domains, including memory, 
attention, inhibitory control, executive functions, and decision making, and that these deficits 
are still present after one week (Meier, Caspi et al. 2012) and one month (Bolla, Eldreth et al. 
2005; Medina, Hanson et al. 2007) of abstinence. Furthermore, an increasing number of 
studies indicate that the magnitude and persistence of cognitive impairment is positively 
associated with the frequency and duration of use and negatively associated with the age of 
onset of heavy cannabis use (Solowij and Pesa 2010; Meier, Caspi et al. 2012). 
It has been suggested that the cognitive impairments observed in healthy cannabis 
users are similar to those reported in patients suffering from schizophrenic psychoses 
(Solowij and Michie 2007). Neuropsychological impairment is recognized as core feature of 
schizophrenia (Palmer, Dawes et al. 2009) and is not only present in patients with 
schizophrenic psychoses, but already in individuals with an at-risk mental state (ARMS) for 
psychosis (Brewer, Wood et al. 2006; Pflueger, Gschwandtner et al. 2007; Riecher-Rossler, 
Pflueger et al. 2009; Giuliano, Li et al. 2012). Furthermore, it has been reported that ARMS 
individuals with later transition to psychosis perform worse on tests measuring verbal fluency, 
memory (Fusar-Poli, Deste et al. 2012; Van der Meer 2012) as well as speed of information 
processing (Brewer, Francey et al. 2005; Riecher-Rossler, Pflueger et al. 2009) than those 
without transition. Accordingly, it has been demonstrated that prediction of psychosis can be 
improved by taking neurocognitive performance measures into account (Riecher-Rossler, 
Pflueger et al. 2009; Koutsouleris, Davatzikos et al. 2012). 
Given that cognitive impairments are frequently present in patients with schizophrenia 
and healthy, heavy cannabis users and given that brain structural changes have been 
observed in cannabis using schizophrenia patients particularly in cannabinoid receptor rich 
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regions (Rapp, Bugra et al. 2012), we would expect cannabis using schizophrenia patients to 
demonstrate particularly severe neurocognitive deficits. Surprisingly, however, the four  most 
recent meta-analyses all demonstrated that schizophrenia patients with a history of cannabis 
use have less impaired cognitive functioning compared with non-using schizophrenia 
patients (Potvin, Joyal et al. 2008; Loberg and Hugdahl 2009; Yucel, Bora et al. 2010; Rabin, 
Zakzanis et al. 2011).  
Two main hypotheses have been put forward to explain these unexpected findings. 
Firstly, it has been proposed that cannabis using schizophrenia patients may belong to a 
subgroup with better pre-morbid functioning and lower vulnerability to psychosis and that, 
therefore, many patients in this subgroup only transitioned to psychosis due to early initiation 
of heavy cannabis use (Schnell, Koethe et al. 2009; Yucel, Bora et al. 2010). This is 
supported by the fact that cannabis using first episode psychosis (FEP) patients consistently 
showed fewer neurological soft signs than FEP patients not using cannabis (Ruiz-Veguilla, 
Callado et al. 2012). The initial neurocognitive performance advantage of this subgroup could 
be so large that it would not be neutralized by the putatively subtle cognitive decline caused 
by cannabis. Secondly, it has been suggested that cannabis could improve cognitive 
functioning by counteracting a putative neurotoxic process related to schizophrenia or by 
stimulating prefrontal neurotransmission (Coulston, Perdices et al. 2011). Although only 
adverse consequences of cannabis use have traditionally been considered in schizophrenia 
research, the latter hypothesis is not as far-fetched as it may seem because a growing body 
of evidence indicates that cannabinoid drugs have a dual neuroprotective-neurotoxic profile 
(Sarne, Asaf et al. 2011). Furthermore, there is evidence from small-scale clinical studies 
that some patients with schizophrenia might benefit from treatment with synthetic Δ-9-
tetradhydrocannabinol (Δ-9-THC), the principle psychoactive constituent of cannabis, as well 
as cannabidiol, which is another constituent of cannabis (Leweke, Koethe et al. 2007; 
Schwarcz, Karajgi et al. 2009). However, while several lines of evidence point to a beneficial 
and even antipsychotic effect of cannabidiol (Roser et al. 2010), the evidence for a beneficial 
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effect of THC is much smaller and more controversial. Moreover, the hypothesis that some 
patients might experience neuroprotective and/or neurocognitive enhancing effects of 
cannabis is difficult to reconcile with results from prospective observational studies showing 
that FEP patients who stopped consuming cannabis have better long-term functional 
outcome and fewer negative symptoms compared to those continuing to consume 
(Gonzalez-Pinto et al., 2011). 
Although a relatively large number of studies have examined associations between 
cannabis use and cognitive performance in schizophrenia patients, most of them have 
serious methodological limitations. For instance, several authors have criticized that many 
studies have not adjusted for potentially confounding variables, measured only a limited 
range of cognitive functions, and used only a single index to classify cannabis use and this 
single index was either not clearly elucidated, was too restricted, and/or tended to be too 
broad , and/or did not consider recency of cannabis use (Coulston, Perdices et al. 2007; 
Segev and Lev-Ran 2012). The latter seems to be particularly important because the most 
recent meta-analysis suggests that the less impaired cognitive performance observed in 
cannabis using schizophrenia patients is mainly driven by the inclusion of lifetime users, 
rather than current or recent users (Yucel, Bora et al. 2010). A further limitation of previous 
studies is that they have not examined whether the associations between cannabis use and 
neuropsychological functioning are stable across different stages of developing psychoses. 
Most studies so far have only included FEP or chronic schizophrenia patients and only one 
study has investigated ARMS patients (Korver, Nieman et al. 2010).  
Hence, the present study for the first time analyzed associations between cannabis 
use and cognitive functioning concomitantly in both ARMS and FEP patients. It also 
improves on many of the previous studies by assessing cognitive functioning across a wide 
range of domains, by adjusting for the most important confounders, by including mostly 
antipsychotic-naïve participants, and by distinguishing between former, current, and never 
users of cannabis. Based on previous findings (Yucel, Bora et al. 2010; Meijer, Dekker et al. 
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2012), we hypothesized that less impaired cognitive functioning would only be present in 
former users of cannabis, but not in current users. In addition, we expected that, within the 
group of current users, cognitive performance would be worse with increasing frequency of 
cannabis use. 
2. Methods 
 
Setting and recruitment 
The neuropsychological data analyzed in this study were collected within the 
prospective Früherkennung von Psychosen (FePsy) study, which aims to improve the early 
detection of psychosis. A more detailed description of the overall study design can be found 
elsewhere (Riecher-Rossler, Gschwandtner et al. 2007; Riecher-Rossler, Pflueger et al. 
2009). Participants were recruited into the study via the FePsy-Clinic at the Psychiatric 
Outpatient Department of the University Hospital Basel, which was set up specifically to 
identify, assess, and treat individuals in the early stages of psychosis. The study was 
approved by the ethics committee of the University of Basel and all participants provided 
written informed consent. 
Screening Procedure 
Screening was performed with the Basel Screening Instrument for Psychosis (BSIP) 
(Riecher-Rossler, Aston et al. 2008).This instrument allows the rating of individuals regarding 
the inclusion/exclusion criteria corresponding to the PACE criteria (Yung, Phillips et al. 1998; 
Yung, McGorry et al. 2007) and has been shown to have a good interrater-reliability (K = .67) 
for the assessment of the main outcome category “at risk for psychosis” and a high predictive 
validity (Riecher-Rössler, Aston et al. 2008). Individuals were classified as being in an At-
Risk Mental State (ARMS) for psychosis, having a first episode psychosis (FEP), or being not 
at risk for psychosis (usually other psychiatric disorders). Only ARMS and FEP individuals 
were included in the present study. 
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Neuropsychological Assessment 
The neuropsychological test battery was mainly based on computer-administered tests. 
All neuropsychological assessments were conducted by psychologists and well-trained, 
supervised advanced students of psychology. The test battery covered the domains of 
general intelligence, executive functions, working memory, attention, verbal learning and 
memory (Pflueger, Gschwandtner et al. 2007; Riecher-Rossler, Pflueger et al. 2009).  
The general intelligence was estimated with the Mehrfachwahl–Wortschatz-Test 
(MWT-A) (Lehrl 1991) and the Leistungsprüfsystem, scale 3 (LPS) (Horn 1983). Both are 
well established German intelligence scales for assessing verbal and nonverbal (abstract 
reasoning) abilities. 
Executive functions were assessed with computer-administered Tower of Hanoi (ToH) 
(Gedika and Schöttke 1994), Wisconsin Card Sorting Test (WCST) (Heaton, Chelune et al. 
1993; Drühe-Wienholt and Wienholt 1998) and Go/No-Go subtest of the Tests for Attentional 
Performance (Zimmermann and Fimm 1993).  
 The working memory was measured with the subtest “Working Memory” of the TAP 
(Zimmermann and Fimm 1993), the selective attention with the subtest Go/No-Go and the 
vigilance with the Continuous Performance Test (CPT-OX) (Rosvold, Mirsky et al. 1956). 
 Verbal learning and memory was assessed by the California Verbal-Learning Test 
(CVLT) (Delis, Kramer et al. 1987). To minimize problems associated with multiple 
comparisons (i.e. Type 1 error inflation), group comparisons on CVLT performance were 
made on the basis of CVLT composite scores instead of individual measures. The following 
three composites were used: auditory attention, verbal learning, and inaccurate recall. These 
composites were derived from a confirmatory factor analysis model that best fitted the data of 
a relatively large sample of epilepsy patients (model 3 in the study of Banos et al. (Banos, 
LaGory et al. 2004)).  
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Psychopathological assessments 
 The Brief Psychiatric Rating Scale (BPRS) (Lukoff, Nuechterlein et al. 1986; Ventura, 
Lukoff et al. 1993) was used to assess positive psychotic symptoms (i.e., hallucinations, 
suspiciousness, unusual thought content and conceptual disorganization) and the Scale for 
Assessment of Negative Symptoms (SANS) (Andreasen 1989) was used to assess negative 
symptoms.  
Cannabis use 
Cannabis use was assessed with the Basel Interview for Psychosis (BIP), a semi-
structured interview that was specifically developed to obtain medical histories of ARMS and 
FEP individuals (Riecher-Rössler et al., in preparation). The BIP contains two items 
assessing the frequency of past and present cannabis use. Both items assess the frequency 
of cannabis use on a five-point ordinal scale using the following response categories: daily, 
several times a week, several times a month, less than several times a month, and not at all. 
Whenever cannabis use was suspected, this was additionally assessed by urine toxicology 
screens, i.e. in 53 (41%) of the included patients. Urine tests were considered positive when 
THC-COOH was present in the urine in a concentration of at least 10µg/l, in order to infer a 
detection window of 1 month. Although urine tests were only available in subset of our 
sample, the agreement between urine tests and the questionnaire item on current use was 
excellent. That is, all patients with cannabis-positive urine had responded to the 
questionnaire item measuring current cannabis use with a frequency of at least rarely and all 
patients with cannabis-negative urine had responded with a frequency less than several 
times per month. Hence, relying only on information of the BIP in those patients who did not 
have urine toxicology screens was considered well justified. 
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 Patients were categorized into three groups: Current, former, and never users. Current 
users were those that had cannabis-positive urine or a current cannabis use frequency of at 
least several times a month. Former users were required to have cannabis-negative urine (if 
available), a past cannabis use frequency of at least several times per month and current 
cannabis use of rarely or never. Never users were required to have cannabis-negative urine 
(if available) and past and current cannabis use frequencies of never. Patients who could not 
be assigned to one of these categories (e.g., because they had consumed cannabis neither 
regularly nor never) were excluded. 
Statistical analysis 
All data were analyzed by using the R environment for statistical computing (R 
Development Core Team 2012). Differences in socio-demographic and clinical 
characteristics between current, former, and never users within each patient group (i.e., 
ARMS, FEP, and combined group) were tested with one-way Analysis of Variance (ANOVA), 
Kruskal Wallis, χ2 or Fisher’s exact tests. 
To investigate the effects of cannabis use (past, former, and never) and patient group 
(ARMS and FEP) on neurocognition, the following procedure was applied. First, all of the 17 
neurocognitive outcome variables were screened for outliers. Values that were 3 standard 
deviations above or below the mean were treated as missing if they could be attributed to 
misunderstanding of instructions and truncated (i.e. replaced by the mean +/- three standard 
deviations) if no obvious cause for their emergence could be found. Because most of the 
neurocognitive outcome measures – even after removal of outliers – did not conform to 
assumptions of normality and/or homogeneity of variance, the Box-Cox transformation (Box 
and Cox 1964) was applied to each of these variables. The Box-Cox procedure automatically 
selected and applied exponential transformations that were optimal with regard to 
normalizing distributions and equalizing variances (see Supplementary Table 1 for the 
chosen transformation of each variable). 
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Because some of the outcome measures, as well as control variables, contained 
considerable proportions of missing data (see Supplementary Table 1), we next performed 
multiple imputation (MI) using the Multivariate Imputation by Chained Equations (MICE) 
software (van Buuren and Groothuis-Oudshoorn 2011). MI is considered the method of 
choice of handling complex incomplete data problems because it yields unbiased parameter 
estimates and standard errors under a missing at random (MAR) or missing completely at 
random (MCAR) missing data mechanism and maximizes statistical power by using all 
available information (Enders 2010). Although the MAR or MCAR assumption is not directly 
testable (Raykov 2011), it was considered plausible in the present situation because the 
variables with the highest proportion of missing values, such as those of the CVLT, resulted 
from changes in the study design over the years and so the probability of being missing was 
unlikely to be directly dependent on the missing values themselves. Furthermore, even if our 
data were missing not at random (MNAR), the MI procedure most likely would have led to 
less biased results than the traditional complete case analysis (cf. Enders 2010, on pages 
40, 80, and 344). To estimate the missing values, we used predictive mean matching and 
sets of predictors restricted to those that correlated with at least 0.1 with the variable to be 
imputed. To protect against a potential power falloff from a too small number of imputations 
(Graham, Olchowski et al. 2007), we generated 100 imputations of the missing values such 
that 100 completed datasets were obtained. The analyses of interest (see below) were then 
conducted in each completed data set, and parameter estimates were pooled according to 
Rubin's rules (Little and Rubin 1987). 
For each neurocognitive outcome variable, an Analysis of Covariance (ANCOVA) was 
conducted. Cognitive functioning was the dependent variable and cannabis use, patient 
group, sex, age, premorbid IQ except for the outcome variable MWT-IQ for which we used 
years of education instead of premorbid IQ, and the cannabis use × patient group interaction 
were independent variables. If the cannabis use × patient group interaction was not 
significant, it was removed from the final models. 
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To investigate whether neurocognition was associated with the frequency of cannabis 
use, additional ANCOVAs were fitted for each neurocognitive outcome variables based on 
the group of current cannabis users only and using the frequency of current cannabis use, 
patient group, sex, age,  premorbid IQ except for the outcome variable MWT-IQ for which we 
used years of education instead of premorbid IQand cannabis frequency × patient group as 
independent variables. Again, if the cannabis frequency × patient group interaction was not 
significant, it was removed from the final models. The analysis was restricted to current 
cannabis use because it was less likely to be subject to recollection bias than past cannabis 
use. Furthermore, the effects of cannabis were less likely to be confounded by the time that 
has elapsed since its last use, which could be up to 10 years in some cases. 
 
3.  Results 
 Sample description 
 
 126 ARMS individuals and 98 FEP patients were recruited into FePsy study from 
March 1, 2000 to April1, 2013. Of these, 18 ARMS and 13 FEP patients were excluded 
because they did not have any cognitive performance measures. In the remaining sample, 3 
ARMS and 8 FEP patients were excluded because they had used cocaine, MDMA, opiates, 
hallucinogens, or amphetamines at least several times per week at some time in their lives. 
Finally, 31 ARMS and 15 FEP patients were excluded because they had neither consumed 
cannabis regularly nor never and therefore could not be assigned to one of the three 
cannabis groups. Analyses were performed on the remaining sample, which consisted of 136 
participants (74 ARMS and 62 FEP patients). The 88 individuals that were excluded from this 
study did not differ from the included individuals with regard to gender, sex, premorbid IQ 
except for the outcome variable MWT-IQ for which we used years of education instead of 
premorbid IQ, patient group frequency, and BPRS total and positive symptoms scores. 
Socio-demographic and clinical characteristics as well as frequencies of cannabis use of the 
included individuals are presented in Table 1. Within the total group and ARMS groups, 
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cannabis groups (i.e., current, former, and never users) were significantly different with 
regard to age. Pairwise comparisons revealed that this was because never users were 
significantly older than former users within both the total (p=0.022) and ARMS (p=0.033) 
groups. There were no significant differences between current, former, and never users of 
cannabis with regard to gender, premorbid IQ except for the outcome variable MWT-IQ for 
which we used years of education instead of premorbid IQ, age at onset of cannabis use, 
BPRS positive symptoms, BPRS total score, SANS total score, and use of antipsychotics, 
tranquilizers, and antidepressives neither within the total group nor within the FEP or ARMS 
subgroups. Almost all ARMS individuals were antipsychotic naïve; only three ARMS 
individuals (3/70) had received low doses of second generation antipsychotic medication 
during no more than three weeks for behavioral control by the referring psychiatrist or 
general practitioner prior to study inclusion.  Also, the majority of the FEP patients (33/56) 
were antipsychotic-naïve.  
 Effects of cannabis use and patient group on cognitive functioning 
In the ANCOVA models that included recency of cannabis use (current, former and 
never use) and patient group (ARMS vs. FEP) as between subject factors and sex, age, 
premorbid IQ except for the outcome variable MWT-IQ for which we used years of education 
instead of premorbid IQ, and use of antipsychotics as covariates, there were no significant 
interactions effects between recency of cannabis use and patient group on any cognitive 
performance measure. The main effect of recency of cannabis use (former, past and never 
use) was only significant for the dependent variable Go/NoGo omissions. Inspections of the 
regression coefficients of the two dummy variables formed from the categorical variable 
recency of cannabis use indicated that this was because both former and current users had 
fewer omissions than never users. However, these differences were no longer significant 
when p-values were corrected for multiple testing by the Benjamini-Hochberg method 
(Benjamini and Hochberg 1995). Figure 1 displays the performance differences of current 
and former users compared to never users on all analyzed cognitive performance measures 
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in the total group. Supplementary Table 2 provides effect sizes (Cohen’s d), confidence 
intervals, test statistics and p-values of the cannabis group differences in the total group. 
Supplementary Figure 1-2 and Supplementary Table 3-4 report about the same differences 
separately for ARMS and FEP patients. 
 As shown in Figure 2, FEP patients tended to have lower cognitive performance than 
ARMS individuals on most cognitive measures. However, the differences between these two 
groups were only statistical trends for the number of omissions in the Go/NoGo task (p= 
0.071) and for the number of omissions in the CPT task (p=0.069). 
 
Cannabis frequency and cognitive functioning 
 In the analyses restricted to current users, the interaction between patient group and 
cannabis frequency (daily, weekly, and less than weekly use of cannabis) was not 
statistically significant for any of the cognitive performance measures, as can be seen in 
Figure 3.. Supplementary Table 5 provides effect sizes (Cohen’s d), confidence intervals, test 
statistics and p-values of these differences in the total group. Supplementary Figure 3-4 and 
Supplementary Table 6-7 report about the same differences separately for ARMS and FEP 
patients. 
 
4. Discussion 
In this study, we examined for the first time the effects of cannabis use on 
neuropsychological performance in a combined sample of FEP and ARMS participants. We 
hypothesized that - compared to never users of cannabis – less impaired  cognitive 
functioning would only be present in former users, but not in current users of cannabis and 
that, within the group of current users, high cannabis use frequency would be associated with 
worse cognitive performance. Both hypotheses were not confirmed in the present study. 
Except for a small significant difference in the number of omissions during Go/NoGo trials, 
which did not withstand correction for multiple testing, there were no cognitive performance 
differences between former, current, and never users of cannabis. Furthermore, we did not 
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find worse cognitive performance with increased cannabis use frequency within the group of 
current users. 
The rejection of the first hypothesis in the present study stands in contrast to the four 
most recent meta-analyses  (Potvin, Joyal et al. 2008; Loberg and Hugdahl 2009; Yucel, 
Bora et al. 2010; Rabin, Zakzanis et al. 2011) , which found less impaired cognitive 
functioning in schizophrenia patients with a history of cannabis use, and to several studies 
indicating that this difference might be due to the inclusion of former users (Yucel, Bora et al. 
2010; Meijer, Dekker et al. 2012). There are multiple possible reasons for these 
discrepancies: First, while most of the studies defined the group of cannabis users according 
to diagnostic criteria of cannabis abuse or dependence using Structured Clinical Interview 
(SCID) for DSM-IV (Coulston, Perdices et al. 2007), we assessed cannabis use with a semi-
structured interview and by urine toxicology screens. The use of the SCID criteria might have 
led to the inclusion of more heavy users than in our study. Furthermore, in other studies, the 
cannabis-naïve group was often defined by the absence of a DSM-IV cannabis use disorder, 
which, unlike in our study, might have led to the inclusion of occasional cannabis users or 
more frequent and heavy users whose functioning is unaffected to the extent in which an 
substance use disorder diagnosis is made.  
Second, the discrepancy between our and other studies might be due to differences 
in neuropsychological test batteries. For instance, some of the neuropsychological 
performance measures, such as the number of omissions in the Go/NoGo and working 
memory task were subject to strong floor effects (i.e., a relatively large number of subjects 
had zero omissions). Thus, it is possible that these measures did not differentiate enough 
between groups with different cognitive functioning. On the other hand, we neither found 
differences in the cognitive measures that were not subject to floor or ceiling effects.  
Finally, we might have obtained different results because our participants consumed 
cannabis with different potency and cannabinoid ratios than in other studies. A growing 
number of studies suggest that THC and cannabidiol, which are both contained in cannabis 
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products with varying concentration, have opposite effects on cognition (Bhattacharyya, 
Morrison et al. 2010). Data suggest diverging trends across Europe in the mean level of THC 
of cannabis in recent years, with a decrease or stabilisation in some countries and an 
increase in other countries (King 2008). 
The rejection of our second hypothesis is in line with other studies, which also did not 
find schizophrenia patients who used cannabis daily or weekly performing significantly worse 
than participants with less frequent use of cannabis (Rodriguez-Sanchez, Ayesa-Arriola et al. 
2010; Meijer, Dekker et al. 2012). Although this seems counterintuitive, one explanation 
might be that daily and weekly users of cannabis to some extent became tolerant to the 
negative effects of cannabis. Meijer et al. (Meijer, Dekker et al. 2012), who also did not find a 
dose-response effect, speculated that the classification of frequency in daily, weekly and 
monthly use might not be sensitive enough to detect cognitive differences.  
 The following limitations should be taken into account: We did not assess the 
duration, quantities of cannabis use, concentration of cannabidiol and THC, and maximum 
frequency of use over the life time. Consequently, we could not control for these influences. 
Furthermore, the moderate sample size of the present study precluded the detection of small 
effects. This could be particularly problematic because some studies indicate that cognitive 
performance differences between cannabis use groups are rather small (Meijer, Dekker et al. 
2012). However, we also did not find statistical trends for differences in cognitive functioning 
in most variables even without correction for multiple testing. Furthermore, the sign of the 
differences between groups was quite heterogeneous. Moreover, Yücel et al. (2010) found in 
their meta-analysis that the difference between lifetime/past cannabis users with never users 
on global cognition has an average effect size of Cohen's d = 0.55. If we take this as an 
estimate of the population effect size and calculate power based on a two sample t-test with 
group sizes equal to our study, a significance level of 0.05, and a two-tailed hypothesis test, 
we get an estimated power of 0.7 for testing the main effect of interest in our study. Hence, 
we consider it rather unlikely that our hypotheses were mainly rejected due to insufficient 
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statistical power. It should also be noted that, although our sample size was moderate, it was 
still larger than in most previous studies (cf., Rabin, Zakzanis et al. 2011). 
In conclusion, the results of the present study do not support the notion that FEP and 
ARMS participants with a history of cannabis use have less impaired cognitive functioning. 
We also found no evidence that the less impaired cognitive functioning in cannabis using 
FEP patients, which has been reported in some previous studies, is due to the inclusion of 
former users or that associations between cannabis use and cognitive functioning differ 
between ARMS and FEP patients.  
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